Chemistry:AN-788
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Other names | NSD-788 |
| Drug class | Monoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor |
| Identifiers | |
| CAS Number | |
AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder.[1][2][3] It was also under development for anxiety disorders, but development for this indication was discontinued.[1] The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI).[1][2][3] As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder.[4]
See also
References
- ↑ 1.0 1.1 1.2 "Initiator Pharma". 8 November 2018. https://news.cision.com/initiator-pharma/r/initiator-pharma-signs-option-agreement-for-phase-2-ready-drug-candidate,c2666860.
- ↑ 2.0 2.1 "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opinion on Therapeutic Patents 24 (2): 131–154. February 2014. doi:10.1517/13543776.2014.859676. PMID 24289044.
- ↑ 3.0 3.1 "New Trends in Antidepresent Drug Research". Transporters as Drug Targets. Wiley. 16 December 2016. pp. 36–. ISBN 978-3-527-67951-5. https://books.google.com/books?id=eVO9DQAAQBAJ&pg=PA36.
- ↑ "Initiator Pharma signs option agreement for Phase 2 ready drug candidate" (in en). 8 November 2018. https://news.cision.com/initiator-pharma/r/initiator-pharma-signs-option-agreement-for-phase-2-ready-drug-candidate,c2666860.
 |  |
